(Q36616503)

15 August 2017

1 reference

title

Docetaxel in the treatment of gastric cancer (English)

1 reference

15 August 2017

1 reference

Peter C Thuss-Patience

series ordinal

1

1 reference

15 August 2017

Albrecht Kretzschmar

series ordinal

2

1 reference

15 August 2017

Peter Reichardt

series ordinal

3

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 October 2006

1 reference

15 August 2017

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

5

1 reference

15 August 2017

page(s)

603-620

1 reference

Global cancer statistics, 2002

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Epidemiology of upper gastrointestinal malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Randomised comparison of fluorouracil, epidoxorubicin and methotrexate (FEMTX) plus supportive care with supportive care alone in patients with non-resectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Prospective randomized trial comparing mitomycin, cisplatin, and protracted venous-infusion fluorouracil (PVI 5-FU) With epirubicin, cisplatin, and PVI 5-FU in advanced esophagogastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Sequential high-dose methotrexate and fluorouracil combined with doxorubicin--a step ahead in the treatment of advanced gastric cancer: a trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Grou

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Evolving chemotherapy for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of oxaliplatin, fluorouracil, and folinic acid in locally advanced or metastatic gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of weekly oxaliplatin plus infusional fluorouracil and folinic acid (FUFOX regimen) as first-line treatment in metastatic gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

A phase II study of biweekly oxaliplatin plus infusional 5-fluorouracil and folinic acid (FOLFOX-4) as first-line treatment of advanced gastric cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II trial of biweekly infusional fluorouracil, folinic acid, and oxaliplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of capecitabine plus cisplatin as first-line chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Multicenter phase II trial of S-1 plus cisplatin in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Combination of irinotecan (CPT-11) plus oxaliplatin (L-OHP) as first-line treatment in locally advanced or metastatic gastric cancer: a multicentre phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of a combination of irinotecan and cisplatin against metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Irinotecan in combination with 5-fluorouracil and folinic acid or with cisplatin in patients with advanced gastric or esophageal-gastric junction adenocarcinoma: results of a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Randomized multicenter phase II trial of a biweekly regimen of fluorouracil and leucovorin (LV5FU2), LV5FU2 plus cisplatin, or LV5FU2 plus irinotecan in patients with previously untreated metastatic gastric cancer: a Federation Francophone de Cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

A phase II study of paclitaxel, weekly, 24-hour continous infusion 5-fluorouracil, folinic acid and cisplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of paclitaxel and carboplatin in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in the management of metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Comparison of antiangiogenic activities using paclitaxel (taxol) and docetaxel (taxotere).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Preclinical experience with docetaxel in gastrointestinal cancers

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Potential for improvement of docetaxel-based chemotherapy: a pharmacological review

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Limited cerebrospinal fluid penetration of docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel (Taxotere) in advanced gastric cancer: results of a phase II clinical trial. EORTC Early Clinical Trials Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: the Eastern Cooperative Oncology Group (ECOG) results of protocol E1293.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Frontline treatment of advanced gastric cancer with docetaxel and granulocyte colony-stimulating factor (G-CSF): a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel 75 mg/m(2) is active and well tolerated in patients with metastatic or recurrent gastric cancer: a phase II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel, 5-fluorouracil, and leucovorin as treatment for advanced gastric cancer: results of a phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

A phase II study of infusional 5-fluorouracil and low-dose leucovorin with docetaxel for advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel and continuous-infusion fluorouracil versus epirubicin, cisplatin, and fluorouracil for advanced gastric adenocarcinoma: a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Paclitaxel versus docetaxel for advanced gastric cancer: a randomized phase II trial in combination with infusional 5-fluorouracil

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

A phase II study of capecitabine and docetaxel combination chemotherapy in patients with advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Weekly docetaxel in combination with capecitabine in patients with metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of docetaxel and capecitabine in patients with metastatic or recurrent gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel and capecitabine in patients with metastatic adenocarcinoma of the stomach and gastroesophageal junction: a phase II study from the North Central Cancer Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase I pharmacokinetic study of S-1 plus cisplatin in patients with advanced gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of docetaxel and irinotecan combination chemotherapy in metastatic gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel (Taxotere)-cisplatin (TC): an effective drug combination in gastric carcinoma. Swiss Group for Clinical Cancer Research (SAKK), and the European Institute of Oncology (EIO).

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Combination chemotherapy with docetaxel and cisplatin for locally advanced and metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel plus cisplatin as second-line therapy in metastatic or recurrent advanced gastric cancer progressing on 5-fluorouracil-based regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

A phase II study of docetaxel and cisplatin in patients with gastric cancer recurring after or progressing during 5-FU/platinum treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

5-Fluorouracil as protracted continuous intravenous infusion can be added to full-dose docetaxel (Taxotere)-cisplatin in advanced gastric carcinoma: a phase I-II trial

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Medical problems in patients with malignancy: case 2. Wernicke's encephalopathy: an unusual acute neurologic complication of lymphoma and its therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II multi-institutional randomized trial of docetaxel plus cisplatin with or without fluorouracil in patients with untreated, advanced gastric, or gastroesophageal adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase II study of low-dose docetaxel/fluorouracil/cisplatin in metastatic gastric carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel + 5-fluorouracil + cisplatin 3-day combination chemotherapy as a first-line treatment in patients with unresectable gastric cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Docetaxel (Taxotere), cisplatin, UFT, and leucovorin combination chemotherapy in advanced gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Randomized phase II trial of either fluorouracil, parenteral hydroxyurea, interferon-alpha-2a, and filgrastim or doxorubicin/docetaxel in patients with advanced gastric cancer with quality-of-life assessment: eastern cooperative oncology group study

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Combination chemotherapy with epirubicin, docetaxel and cisplatin (EDP) in metastatic or recurrent, unresectable gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Epirubicin, cisplatin and docetaxel combination therapy for metastatic gastric cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

Phase I to II study of pleurectomy/decortication and intraoperative intracavitary hyperthermic cisplatin lavage for mesothelioma

21 January 2018

1 reference

https://api.crossref.org/works/10.2217%2F14796694.2.5.603

21 January 2018

Identifiers

DOI

10.2217/14796694.2.5.603

1 reference

15 August 2017

1 reference